A new vaccine against the coronavirus is produced by a French pharmaceutical company and is expected to be more than 80% effective. The new jab named Valneva should be ready at the end of the year with a technology different from the products already on the market.
“Based on (…) the phase I and II trials, we hope to have a vaccine that is effective in more than 80% of cases. It will have to be demonstrated in the phase III trial, ”said Franck Grimaud. .
The efficacy would therefore be lower than that of messenger RNA vaccines, such as those from Pfizer / BioNTech or Moderna, which are around 95%, but it would be higher than that of the AstraZeneca and Johnson & Johnson vaccines, which are between 60 and 70%. effective.
Some in France are snubbing the vaccines already available to wait for the new antidote, as suggested by the French boss of Sanofi, another French pharmaceutical company which hopes to put its vaccine on the market this year, Olivier Bogillot.
“Waiting only increases the risk and prolongs the circulation of the virus.
“The vaccines authorized by the Health Authorities are safe and effective. “
Valneva uses a deactivated virus vaccine, a technology more traditional than RNA, and which is used in particular for influenza vaccines each year, said Franck Grimaud.
“There are many parameters to consider in a vaccine: efficacy, safety, duration of protection, duration between the first two doses and need for a booster …”, continued Franck Grimaud.
READ MORE: Defense ministry warns ex-sailor to ‘slaughter’ animals on Kabul trail
Reports suggest the UK has secured an order for 190 million doses over five years.
Delivery of the first 60 million of the 100 million doses ordered by the UK government is expected to continue in the first quarter of next year, with the remainder also due in 2022.
UK authorities have options for an additional 90million doses to be delivered between 2023 and 2025, which would bring the total order value to € 1.4 billion (£ 1.2 billion).
Discussions started in early 2020 were aborted, on the grounds that “the French company had not fulfilled the conditions” for marketing in Europe.
In an interview in April, after Valneva called off the talks, chief executive Thomas Lingelbach said they had “gone around in circles” without moving forward.
Valneva indicates on its site that discussions resumed with the European Commission in January, and are “still ongoing” in July 2021.
Additional reporting by Maria Ortega